Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6597471
Reference Type
Journal Article
Title
Vas deferens, a site of male contraception: an overview
Author(s)
Lohiya, NK; Manivannan, B; Mishra, PK; Pathak, N; ,
Year
2001
Is Peer Reviewed?
Yes
Journal
Asian Journal of Andrology
ISSN:
1008-682X
EISSN:
1745-7262
Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
Location
MUMBAI
Volume
3
Issue
2
Page Numbers
87-95
Language
English
PMID
11404791
Web of Science Id
WOS:000169801100002
URL
https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034946679&partnerID=40&md5=34f660c32cb6094b5073e75dc21cee1c
Exit
Abstract
The vas deferens is a site which can be exploited for male contraception without undue side effects. The only effective technique available for male contraception is vasectomy, being practiced world wide, despite that it is a permanent surgical procedure and its successful reversal is not assured. Although no-scalpel vasectomy minimizes surgical procedures, the fate of its reversal is akin to that of vasectomy. Several occlusive and non-occlusive vasal procedures which claim to be reversible without surgical intervention, possess more disadvantages than advantages. Vas occlusion with plug, 'Shug' or medical grade silicone rubber, although claimed to produce reversible azoospermia without affecting spermatogenesis, requires skilled microsurgery for their implantation and later removal. RISUG, a non-sclerotic polymer styrene maleic anhydride (SMA), could be more advantageous than vasectomy and other vas occlusive procedures in that it could be a totally non-invasive procedure by "no-scalpel injection" and "non-invasive reversal". It is claimed to offer long-term contraception without adverse side effects and also to be possible as a male spacing method by repeated vas occlusion and non-invasive reversal. The drug is currently under multicentre Phase III clinical trial.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity